Meningococcal B vaccine prompts immune responses against gonorrhea in trial
A phase II clinical trial showed that the 4CMenB meningococcal vaccine generates blood and mucosal antibodies against gonorrhea antigens in healthy adults.
FTMQ Health, written by our newsroom0 views
A randomized phase II clinical trial at Emory University found that the licensed four-component meningococcal serogroup B vaccine, 4CMenB, stimulates systemic and mucosal antibody responses against gonorrhea antigens in healthy adults, Bioengineer.org reported. The study showed that the vaccine induced serum antibodies and mucosal immunoglobulin G responses against outer membrane vesicles of Neisseria gonorrhoeae. [1]
Researchers evaluated immune responses in 52 healthy volunteers aged 18 to 49 years who had no prior history of gonorrhea and were at low risk for acquiring the infection. Bioengineer.org reported that participants were randomly assigned in a four-to-one ratio in the double-blind, placebo-controlled trial. [1]
Neisseria gonorrhoeae is an obligate human pathogen bacterium that primarily colonizes the mucosal lining of the urogenital tract. It causes the sexually transmitted infection gonorrhea as well as other gonococcal diseases such as septic arthritis and disseminated gonococcemia. The bacterium can also adhere to the mucosa of the rectum, pharynx, nose, and conjunctiva. [2]
Meningococcal disease is a serious bacterial infection caused by Neisseria meningitidis that presents as life-threatening meningitis or septicemia. The 4CMenB vaccine is designed to protect against meningococcal serogroup B, which can otherwise cause rapid septic shock and organ failure. [1][4]
In short
- A phase II trial showed the 4CMenB vaccine generates antibodies against Neisseria gonorrhoeae antigens.
- The Emory University trial evaluated 52 healthy adults aged 18 to 49 years with no prior history of gonorrhea.
- Participants received either the 4CMenB vaccine or a placebo in a four-to-one randomized ratio.
- Neisseria gonorrhoeae is a bacterium that primarily targets the mucosal lining of the human urogenital tract.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Meningococcal B Vaccine Generates Systemic and Mucosal Antibodies Against Gonorrhea AntigensBioengineer.org, 2d ago (the report this story comes from)
Background
- [2]Neisseria gonorrhoeae on Wikipedia
- [3]BCG vaccine on Wikipedia
- [4]Meningococcal disease on Wikipedia
Our newsroom writes these reports with the help of software, from the 4 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Trial evaluates one week intradermal rabies vaccine regimen in adult trialMedical Science, 19d ago
- Phase III breast cancer study tests reduced post surgery therapyMedical Science, 21d ago
- CAR T cell therapy analysis reveals high inflammation but low mortalityMedical Science, 4h ago
- Adults comprise two thirds of cases in Pennsylvania measles outbreakPublic Health, 23d ago
- RIPK1 Inhibitors Match Placebo Safety in Human Clinical TrialsMedical Science, 2d ago
More in Medical Science
- CAR T cell therapy analysis reveals high inflammation but low mortality4h ago
- Diets rich in dairy and fruit linked to child height growth1d ago
- RIPK1 Inhibitors Match Placebo Safety in Human Clinical Trials2d ago
- Frontiers in Psychiatry collection highlights music interventions for mental health3d ago
- Shanghai dismisses researchers after gene editing trial death3d ago
- Trial in Mali tests azithromycin impacts on infant antimicrobial resistance4d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.